Adaptive Biotechnologies President and COO Julie Rubinstein Sells $1.05M of Stock
Julie Rubinstein, President and COO, sold 35,228 shares of Adaptive Biotechnologies Corp at $28.93 to $31.22 a share (average $29.73) in 4 transactions, worth $1.05M in total between Nov 11, 2026 and Nov 13, 2026. Shares held after the trade: 377,802 (-2.9%).
Adaptive Biotechnologies Chief Commercial Officer, MRD Susan Bobulsky Sells $60K of Stock
Susan Bobulsky, Chief Commercial Officer, MRD, sold 1,875 shares of Adaptive Biotechnologies Corp at $32.00 a share, worth $60K in total on Nov 11, 2026. Shares held after the trade: 387,475 (-0.5%).
Adaptive Biotechnologies President and COO Julie Rubinstein Sells $709K of Stock
Julie Rubinstein, President and COO, sold 23,762 shares of Adaptive Biotechnologies Corp at $28.87 to $30.58 a share (average $29.82) in 5 transactions, worth $709K in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 377,802 (-0.5%).
Adaptive Biotechnologies President and COO Julie Rubinstein Sells $954K of Stock
Julie Rubinstein, President and COO, sold 35,643 shares of Adaptive Biotechnologies Corp at $25.78 to $27.88 a share (average $26.78) in 7 transactions, worth $954K in total between Nov 4, 2026 and Nov 6, 2026. Shares held after the trade: 377,802 (-0.9%).
Adaptive Biotechnologies reported a net loss of $57.2 million for the first nine months of 2026, compared to a $45.9 million loss in the prior year period, impacted by a $23.7 million loss on revenue interest liability extinguishment. Despite the year-to-date loss, the company achieved a quarterly net income of $2.9 million in Q3 2026, though revenue for the quarter decreased to $83.9 million from $94.0 million year-over-year.
Adaptive Biotechnologies reported Q3 2026 financial results, achieving total company profitability ahead of expectations with $83.9 million in revenue and $2.8 million in net income. The company saw 44% growth in core MRD revenue (excluding milestones) and increased its full-year 2026 MRD revenue guidance. Management highlighted momentum in clonoSEQ testing and updated clinical guidelines for multiple myeloma as key growth drivers.
Term
Q3 2026
“Adaptive achieved total company profitability ahead of expectations in Q3 and delivered 44% growth in core MRD revenue. This momentum supports another increase in our full year outlook. Updated guidelines and a new definition of cure for multiple myeloma amplify the need for MRD testing and bolster clonoSEQ’s long-term potential.”
Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies
Adaptive Biotechnologies President and COO Julie Rubinstein Sells $929K of Stock
Julie Rubinstein, President and COO, sold 35,643 shares of Adaptive Biotechnologies Corp at $25.23 to $27.45 a share (average $26.06) in 5 transactions, worth $929K in total between Oct 30, 2026 and Nov 3, 2026. Shares held after the trade: 377,802 (-3.0%).
Adaptive Biotechnologies President and COO Julie Rubinstein Sells $992K of Stock
Julie Rubinstein, President and COO, sold 35,443 shares of Adaptive Biotechnologies Corp at $26.58 to $28.44 a share (average $28.00) in 4 transactions, worth $992K in total between Oct 27, 2026 and Oct 29, 2026. Shares held after the trade: 377,802 (-3.0%).
Adaptive Biotechnologies President and COO Julie Rubinstein Sells $897K of Stock
Julie Rubinstein, President and COO, sold 35,643 shares of Adaptive Biotechnologies Corp at $24.38 to $26.30 a share (average $25.18) in 6 transactions, worth $897K in total between Oct 22, 2026 and Oct 26, 2026. Shares held after the trade: 377,802 (-0.9%).
Adaptive Biotechnologies President and COO Julie Rubinstein Sells $877K of Stock
Julie Rubinstein, President and COO, sold 35,543 shares of Adaptive Biotechnologies Corp at $24.05 to $25.57 a share (average $24.66) in 4 transactions, worth $877K in total between Oct 19, 2026 and Oct 21, 2026. Shares held after the trade: 377,802 (-1.5%).
Adaptive Biotechnologies President and COO Julie Rubinstein Sells $890K of Stock
Julie Rubinstein, President and COO, sold 35,343 shares of Adaptive Biotechnologies Corp at $24.21 to $25.82 a share (average $25.17) in 4 transactions, worth $890K in total between Oct 14, 2026 and Oct 16, 2026. Shares held after the trade: 378,102 (-3.0%).
Adaptive Biotechnologies President and COO Julie Rubinstein Sells $920K of Stock
Julie Rubinstein, President and COO, sold 35,643 shares of Adaptive Biotechnologies Corp at $25.35 to $26.41 a share (average $25.81) in 4 transactions, worth $920K in total between Oct 9, 2026 and Oct 13, 2026. Shares held after the trade: 377,802 (-3.0%).
Adaptive Biotechnologies President and COO Julie Rubinstein Sells $948K of Stock
Julie Rubinstein, President and COO, sold 35,643 shares of Adaptive Biotechnologies Corp at $25.66 to $30.53 a share (average $26.60) in 6 transactions, worth $948K in total between Oct 6, 2026 and Oct 8, 2026. Shares held after the trade: 377,802 (-3.0%).
Adaptive Biotechnologies Chief Commercial Officer, MRD Susan Bobulsky Sells $193K of Stock
Susan Bobulsky, Chief Commercial Officer, MRD, sold 6,444 shares of Adaptive Biotechnologies Corp at $30.00 a share, worth $193K in total on Oct 6, 2026. Shares held after the trade: 389,350 (-1.6%).
Adaptive Biotechnologies President and COO Julie Rubinstein Sells $1.01M of Stock
Julie Rubinstein, President and COO, sold 35,643 shares of Adaptive Biotechnologies Corp at $27.57 to $29.67 a share (average $28.46) in 5 transactions, worth $1.01M in total between Oct 1, 2026 and Oct 5, 2026. Shares held after the trade: 377,802 (-1.4%).
Adaptive Biotechnologies Chief People Officer Francis Lo Sells $758K of Stock
Francis Lo, Chief People Officer, sold 26,792 shares of Adaptive Biotechnologies Corp at $27.52 to $28.61 a share (average $28.28) in 2 transactions, worth $758K in total on Oct 1, 2026. Shares held after the trade: 220,867 (-7.8%).
Adaptive Biotechnologies Chief People Officer Francis Lo Sells $3.24M of Stock
Francis Lo, Chief People Officer, sold 115,406 shares of Adaptive Biotechnologies Corp at $28.02 to $28.57 a share (average $28.06) in 2 transactions, worth $3.24M in total on Sep 16, 2026. Shares held after the trade: 220,867 (-3.4%).